Agilon Health price target lowered to $2 from $5 at Barclays
Barclays lowered the firm's price target on Agilon Health to $2 from $5 and keeps an Underweight rating on the shares. The company's Q3 results underscore the lack of visibility into real-time trends and limited ability to take control of negative developments, the analyst tells investors in a research note.
agilon health, inc. (AGL) Q3 2024 Earnings Call Transcript
agilon health, inc. (NYSE:AGL ) Q3 2024 Earnings Call Transcript November 7, 2024 4:30 PM ET Company Participants Leland Thomas - Senior Manager-Investor Relations Steven Sell - Chief Executive Officer Jeffrey Schwaneke - Chief Financial Officer Conference Call Participants Lisa Gill - JPMorgan Justin Lake - Wolfe Research Adam Ron - Bank of America George Hill - Deutsche Bank Sameer Patel - Evercore Ryan Langston - TD Cowen Stephen Baxter - Wells Fargo Andrew Mok - Barclays Jack Slevin - Jefferies Michael Ha - Baird Thomas Keller - RBC Daniel Grosslight - Citi Operator Good afternoon and thank you for joining the agilon health Third Quarter 2024 Earnings Conference Call.
agilon health Plunges On A Poor Prognosis (Rating Downgrade)
I initially rated agilon health, inc. as a “hold” due to its volatile financial results and uncertain future, but recent developments necessitate a downgrade to 'sell'. The company's stock plummeted 60.1% since my last article, driven by disappointing Q3 results and reduced guidance, despite revenue growth. Rising medical costs and expansion expenses have severely impacted profitability, with a significant increase in net loss and negative EBITDA.
Here's What Key Metrics Tell Us About Agilon (AGL) Q3 Earnings
Although the revenue and EPS for Agilon (AGL) give a sense of how its business performed in the quarter ended September 2024, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
Agilon Health (AGL) Reports Q3 Loss, Lags Revenue Estimates
Agilon Health (AGL) came out with a quarterly loss of $0.29 per share versus the Zacks Consensus Estimate of a loss of $0.10. This compares to loss of $0.06 per share a year ago.
agilon health: Interesting Business Model, But Volatile And Uncertain
agilon hagilon healthealth shares dropped significantly after disappointing financial results, down 11.9% in two days. The company's revenue surged 38.7% year over year, but its net loss nearly doubled, and guidance for 2024 is mixed. Concerns include declining cash reserves, potential for further dilution, and uncertainty regarding share valuation.
AGL Energy Limited (AGLNF) Q4 2024 Earnings Call Transcript
AGL Energy Limited (OTCPK:AGLNF) Q4 2024 Earnings Conference Call August 13, 2024 9:00 PM ET Company Participants Damien Nicks - Managing Director and Chief Executive Officer Gary Brown - Chief Financial Officer Markus Brokhof - Chief Operating Officer Jo Egan - Chief Customer Officer Conference Call Participants Tom Allen - UBS Anthony Moulder - Jefferies Dale Koenders - Barrenjoey Reinhardt van der Walt - Bank of America Merrill Lynch Mark Busuttil - JPMorgan Ian Myles - Macquarie Gordon Ramsay - RBC Capital Markets Rob Koh - Morgan Stanley Nik Burns - Jarden Australia Henry Meyer - Goldman Sachs Australia Operator Thank you for standing by and welcome to the AGL Energy Full-Year Results Briefing Conference Call. All participants will be in a listen-only mode.
Magilon health, inc. (AGL) Q2 2024 Earnings Call Transcript
Magilon health, inc. (NYSE:AGL ) Q2 2024 Earnings Conference Call August 6, 2024 4:30 PM ET Company Participants Leland Thomas - VP, IR Steven Sell - CEO Jeffrey Schwaneke - CFO Conference Call Participants Lisa Gill - JPMorgan Justin Lake - Wolfe Research Stephen Baxter - Wells Fargo Ryan Daniels - William Blair Elizabeth Anderson - Evercore ISI Adam Ron - Bank of America.
Agilon (AGL) Q2 Earnings: Taking a Look at Key Metrics Versus Estimates
While the top- and bottom-line numbers for Agilon (AGL) give a sense of how the business performed in the quarter ended June 2024, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
Agilon Health (AGL) Reports Q2 Loss, Misses Revenue Estimates
Agilon Health (AGL) came out with a quarterly loss of $0.07 per share in line with the Zacks Consensus Estimate. This compares to loss of $0.04 per share a year ago.
IMPORTANT INVESTOR ALERT: The Schall Law Firm Encourages Investors in agilon health, inc. with Losses of $100,000 to Contact the Firm
LOS ANGELES, CA / ACCESSWIRE / May 19, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against agilon health, inc. ("agilon" or "the Company") (NYSE:AGL) for violations of 10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission.
IMPORTANT SHAREHOLDER ALERT: The Schall Law Firm Encourages Investors in agilon health, inc. with Losses of $100,000 to Contact the Firm
LOS ANGELES, CA / ACCESSWIRE / May 18, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against agilon health, inc. ("agilon" or "the Company") (NYSE:AGL) for violations of 10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission.
